Where does Baker Heart AND Diabetes Institute rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Baker Heart AND Diabetes Institute ranks #34,402 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Baker Heart AND Diabetes Institute hold?

Baker Heart AND Diabetes Institute holds 7 US utility patents granted between 2019 and 2025, spanning 8 technology areas.

What is Baker Heart AND Diabetes Institute's Innovation Score?

Baker Heart AND Diabetes Institute has an Innovation Score of 47.7 out of 100 (top 18% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Baker Heart AND Diabetes Institute's patent grant rate increasing or decreasing?

Baker Heart AND Diabetes Institute's recent grant velocity is +200% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Baker Heart AND Diabetes Institute's patents?

Baker Heart AND Diabetes Institute's patents average 17.6 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Baker Heart AND Diabetes Institute patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Baker Heart AND Diabetes Institute

Q: What technology areas does Baker Heart AND Diabetes Institute focus on?

Baker Heart AND Diabetes Institute's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 5 patents. Grants appear in 8 CPC subclasses total.

USPTO PatentsView assignee record - 7 granted patents across 8 technology areas, recorded in grant years 2019–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Baker ranks #34,402 of 49,997 tracked US assignees by granted-patent volume, with 7 patents across 8 technology areas.

#34,402
of 49,997 US assignees by volume: Top 18%
by Innovation Score (47.7/100): 17.6
avg claims per patent: +200%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R34402 · Foreign Corporation #34,402 · 7 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 7 grants
MID-PACK #34,402/49,997
PHOTO-FINISH BAE Systems Rokar…
CPC-NARROW A61P · 8 areas
INNOV-PAR 47.7/100
CLAIMS-RICH 17.6 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-SURGE +200% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: BAE Systems Rokar International Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Baker Heart AND… · this assignee

48
3D Lighting… · lowest

7

What this shows Baker's Innovation Score is 47.7/100 (top 18% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Baker's grants concentrate

Baker Heart AND Diabetes Institute is a focused PatentsView assignee: 8 CPC subclasses with 71.4% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2022 (3 grants) versus a trough of 1 in 2019. By volume, Baker sits between B&W Tek, Inc. and Basf Agricultural Solutions US LLC.

Baker's three-year grant acceleration

Baker Heart AND Diabetes Institute shows 3 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

B&W Tek

7
BAE Systems Rokar…

7
Baili-bio (Chengd…

7
Baimmt

7
Baldwin Jimek AB

7
Balsam Internatio…

7
Bandalux Industri…

7
Basf Agricultural…

7
Baker Heart AND D… ◀

7

What this shows Baker holds 7 patents at rank #34,395, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Baker

By rank, the assignees closest to #34,395 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Baker's primary technology class.

Baker's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

48 Top 18% higher than 82% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2019–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.

View data table

Baker Heart AND Diabetes Institute patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2019	1	14.3%
2022	3	42.9%
2025partial year	3	42.9%

Which technologies does Baker Heart AND Diabetes Institute patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 5

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 4

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 2

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 1

G16H - Healthcare Informatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR THE Handling OR Processing OF Medical OR Healthcare Data 1

C07K - Peptides 1

A01K - Animal HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; Rearing OR Breeding Animals, NOT Otherwise Provided FOR; NEW Breeds OF Animals 1

A61B - DIAGNOSIS; SURGERY; Identification 1

Top 8 of 8 technology areas

Where it ranks

Overall rank by patents

#34,402

of 49,997 tracked assignees

Innovation Score

47.7 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Baker Heart AND Diabetes Institute's patent record in context - here's where to go next.

Baker Heart AND Diabetes Institute's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 71.4% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #34,402 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Baker Heart AND Diabetes Institute against B&W Tek, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 47.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.